Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

被引:0
|
作者
Joanna Achinger-Kawecka
Fatima Valdes-Mora
Phuc-Loi Luu
Katherine A. Giles
C. Elizabeth Caldon
Wenjia Qu
Shalima Nair
Sebastian Soto
Warwick J. Locke
Nicole S. Yeo-Teh
Cathryn M. Gould
Qian Du
Grady C. Smith
Irene R. Ramos
Kristine F. Fernandez
Dave S. Hoon
Julia M. W. Gee
Clare Stirzaker
Susan J. Clark
机构
[1] Garvan Institute of Medical Research,Epigenetics Research Laboratory, Genomics and Epigenetics Theme
[2] UNSW Sydney,St. Vincent’s Clinical School, Faculty of Medicine
[3] The Kinghorn Cancer Centre,Cancer Theme
[4] John Wayne Cancer Institute,Department of Translational Molecular Medicine
[5] Cardiff University,Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences
来源
Nature Communications | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer.
引用
收藏
相关论文
共 50 条
  • [1] Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
    Achinger-Kawecka, Joanna
    Valdes-Mora, Fatima
    Luu, Phuc-Loi
    Giles, Katherine A.
    Caldon, C. Elizabeth
    Qu, Wenjia
    Nair, Shalima
    Soto, Sebastian
    Locke, Warwick J.
    Yeo-Teh, Nicole S.
    Gould, Cathryn M.
    Du, Qian
    Smith, Grady C.
    Ramos, Irene R.
    Fernandez, Kristine F.
    Hoon, Dave S.
    Gee, Julia M. W.
    Stirzaker, Clare
    Clark, Susan J.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [2] Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer
    Pathiraja, Thushangi N.
    Nayak, Shweta R.
    Xi, Yuanxin
    Jiang, Shiming
    Garee, Jason P.
    Edwards, Dean P.
    Lee, Adrian V.
    Chen, Jian
    Shea, Martin J.
    Santen, Richard J.
    Gannon, Frank
    Kangaspeska, Sara
    Jelinek, Jaroslav
    Issa, Jean-Pierre J.
    Richer, Jennifer K.
    Elias, Anthony
    McIlroy, Marie
    Young, Leonie S.
    Davidson, Nancy E.
    Schiff, Rachel
    Li, Wei
    Oesterreich, Steffi
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (229)
  • [3] The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
    Joanna Achinger-Kawecka
    Clare Stirzaker
    Neil Portman
    Elyssa Campbell
    Kee-Ming Chia
    Qian Du
    Geraldine Laven-Law
    Shalima S. Nair
    Aliza Yong
    Ashleigh Wilkinson
    Samuel Clifton
    Heloisa H. Milioli
    Sarah Alexandrou
    C. Elizabeth Caldon
    Jenny Song
    Amanda Khoury
    Braydon Meyer
    Wenhan Chen
    Ruth Pidsley
    Wenjia Qu
    Julia M. W. Gee
    Anthony Schmitt
    Emily S. Wong
    Theresa E. Hickey
    Elgene Lim
    Susan J. Clark
    Nature Structural & Molecular Biology, 2024, 31 : 498 - 512
  • [4] The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
    Achinger-Kawecka, Joanna
    Stirzaker, Clare
    Portman, Neil
    Campbell, Elyssa
    Chia, Kee-Ming
    Du, Qian
    Laven-Law, Geraldine
    Nair, Shalima S.
    Yong, Aliza
    Wilkinson, Ashleigh
    Clifton, Samuel
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Song, Jenny
    Khoury, Amanda
    Meyer, Braydon
    Chen, Wenhan
    Pidsley, Ruth
    Qu, Wenjia
    Gee, Julia M. W.
    Schmitt, Anthony
    Wong, Emily S.
    Hickey, Theresa E.
    Lim, Elgene
    Clark, Susan J.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2024, 31 (03) : 498 - 512
  • [5] Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
    Dimitrakopoulos, Foteinos-Ioannis
    Kottorou, Anastasia
    Tzezou, Aspasia
    CANCER LETTERS, 2021, 517 : 55 - 65
  • [6] Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer
    Lu, Yunlong
    Liu, Wukun
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (24) : 15094 - 15114
  • [7] Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer
    Nicholson, RI
    Hutcheson, IR
    Harper, ME
    Knowlden, JM
    Barrow, D
    McClelland, RA
    Jones, HE
    Wakeling, AE
    Gee, JMW
    HORMONE-RELATED TUMORS: NOVEL APPROACHES TO PREVENTION AND TREATMENT, 2002, 963 : 104 - 115
  • [8] Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
    Yubo Wang
    Jian Min
    Xiangping Deng
    Tian Feng
    Hebing Hu
    Xinyi Guo
    Yan Cheng
    Baohua Xie
    Yu Yang
    Chun-Chi Chen
    Rey-Ting Guo
    Chune Dong
    Hai-Bing Zhou
    Acta Pharmaceutica Sinica B, 2023, (12) : 4963 - 4982
  • [9] Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
    Wang, Yubo
    Min, Jian
    Deng, Xiangping
    Feng, Tian
    Hu, Hebing
    Guo, Xinyi
    Cheng, Yan
    Xie, Baohua
    Yang, Yu
    Chen, Chun-Chi
    Guo, Rey-Ting
    Dong, Chune
    Zhou, Hai-Bing
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (12) : 4963 - 4982
  • [10] Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
    Pancholi, Sunil
    Simigdala, Nikiana
    Ribas, Ricardo
    Schuster, Eugene
    Leal, Mariana Ferreira
    Nikitorowicz-Buniak, Joanna
    Rega, Camilla
    Bihani, Teeru
    Patel, Hitisha
    Johnston, Stephen R.
    Dowsett, Mitch
    Martin, Lesley-Ann
    NPJ BREAST CANCER, 2022, 8 (01)